AI ScreeningAI ChatPricing
  1. US-listed companies
  2. Akari Therapeutics Plc
  3. Financials
  4. Cash from operations

Akari Therapeutics Plc【AKTX】

Market cap
$16.5B
P/E ratio
SummaryFinancials
Period EndCash from operations (Million USD)YoY (%)
Dec 31, 2024-13-23.61%
Dec 31, 2023-16-23.59%
Dec 31, 2022-22+14.10%
Dec 31, 2021-19+11.19%
Dec 31, 2020-17+31.21%
Dec 31, 2019-13-42.79%
Dec 31, 2018-23-28.54%
Dec 31, 2017-32+28.32%
Dec 31, 2016-25+395.90%
Dec 31, 2015-5-47.52%
Dec 31, 2014-9+73.60%
Dec 31, 2013-5

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)